About Geneombio Technologies Private Limited
Data last updated: 12 February 2026
Geneombio Technologies Private Limited is a private limited company based in Haveli, Maharashtra, India, a subsidiary of Resilient Cosme-Ceuticals Private Limited. It specialises in diagnostic centers and pathology labs, a part of the broader healthcare sector. Incorporated on 06 July 2005, the company has been in operation for over 21 years.
Registered with ROC Pune under CIN U24239PN2005PTC020977.
Capital: an authorised share capital of ₹2.85 Cr and a paid-up capital of ₹2.8 Cr. Formerly known as Geneom Biotech Private Limited. It is led by directors Yashwant Govind Chavan and Sachin Sharad Purohit.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Haveli, Maharashtra.
As per the financials filed for FY 2024, the company reported a revenue of ₹6.07 Cr, a growth of 35% compared to the previous year.
The company has a workforce of approximately 29 employees as per the latest available data. It operates as a subsidiary of Resilient Cosme-Ceuticals Private Limited.
The company is associated with 1 brand - Geneombio Technologies. As per MCA filings, the company has open charges of ₹1.87 Cr and satisfied charges of ₹3.6 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website geneombiotechnologies.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressOffice No. 302 Third Floor Lalani Quantum, Survey No. 322/A 323/1A 324/1A, Haveli, Maharashtra, India – 411021
-
IndustryHealthcare, Diagnostic Centers & Pathology Labs
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Geneombio Technologies Private Limited
Geneombio Technologies Private Limited operates one associated brand: Geneombio Technologies. These brands represent Geneombio Technologies Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Molecular diagnostic, contract research, and animal genetic services are provided. | geneombiotechnologies.com |
Competitors & Alternatives of Geneombio Technologies Private Limited
Brands and companies operating in the same space as Geneombio Technologies Private Limited include Alderley Analytical, BioAgilytix, Lightcast Discovery and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Alderley Analytical
|
Bioanalytical assays for drug development are developed and validated. | Stockport, United Kingdom, United Kingdom | 2013 |
BioAgilytix
|
Large-molecule bioanalysis is provided for biologics and biosimilars development. | Durham, United States, United States | 2008 |
Lightcast Discovery
|
Advanced single-cell analysis solutions are provided for biotechnology research. | Cambridge, United Kingdom, United Kingdom | 2019 |
Solvias
|
Integrated R&D services are provided for pharmaceuticals and allied sectors. | Kaiseraugst, Switzerland, Switzerland | 1999 |
Tentamus
|
Analytical and quality assurance services are provided for diverse industries. | Berlin, Germany, Germany | 2011 |
Nordic Bioscience
|
Preclinical and clinical drug development CRO with proprietary in-house Biomarker platform | Herlev, Denmark, Denmark | 1996 |
Advion
|
Microfluidics and mass spectrometry products are provided for clinical research. | Ithaca, United States, United States | 1993 |
Synexa Life Sciences
|
Provider of comprehensive analytical and advisory services, specializing in biomarker services | Cape Town, South Africa, South Africa | 2003 |
ApoCell
|
Provider of clinical trial and clinical development on bioanalytical services | Houston, United States, United States | 2004 |
Evans Analytical Group
|
Company offering a suite of scientific services for materials, engineering, agri, and life science industries | San Diego, United States, United States | 1978 |
Business Activity of Geneombio Technologies Private Limited
Geneombio Technologies Private Limited is engaged in multiple principal business activities such as hospital and medical care, professional, scientific and technical, and trade, with detailed activities including medical and dental practice, nursing, pathology, blood bank services, etc., other professional, scientific and technical activities, wholesale trading. The company has 3 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q2 | Medical and dental practice, Nursing, pathology, blood bank services, etc. | ********* |
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities | ********* |
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Geneombio Technologies Private Limited
Geneombio Technologies Private Limited is audited by S.D.DALE & COMPANY for the financial year 2022. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| S.D.DALE & COMPANY | blur-value | blur-value | blur-value |
Board of Directors of Geneombio Technologies Private Limited
Geneombio Technologies Private Limited is currently managed by 2 directors, with 10 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Yashwant Govind Chavan
Also directs:
Precibio Lifesciences Llp
|
Director | 01 Feb 2021 | 5 Years 5 Months | Current |
|
Sachin Sharad Purohit
Also directs:
Precibio Lifesciences Llp, Panakos Food And Beverages Private Limited, Hygge Brew Private Limited and 1 more
|
Director | 06 Jul 2005 | 21 Years 0 Months | Current |
Financials of Geneombio Technologies Private Limited FY 2025 filings available
Geneombio Technologies Private Limited reported revenue of ₹6.07 Cr (up 35% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Geneombio Technologies Private Limited
As of FY 2022, Geneombio Technologies Private Limited's shareholding pattern shows 93.97% by promoters, 6.03% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Geneombio Technologies Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Sep 2018 | Yes Bank Limited | ₹1.87 Cr | Open |
| 26 Jun 2013 | Canara Bank | ₹50 Lakh | Satisfied |
| 17 Jun 2006 | The Suvarna Sahakari Bank Ltd. | ₹30 Lakh | Satisfied |
| 29 Aug 2005 | The Suvarna Sahakari Bank Ltd. | ₹2.8 Cr | Satisfied |
Total charge records: 4 View all charges
Employees and EPFO Compliance at Geneombio Technologies Private Limited
Geneombio Technologies Private Limited has a workforce of 29 employees as of Apr 10, 2024.
Employee Count & EPFO Data of Geneombio Technologies Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Geneombio Technologies Private Limited
GSTIN & GST Filing Data of Geneombio Technologies Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Geneombio Technologies Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Geneombio Technologies Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Geneombio Technologies Private Limited
MSME Payment Delays by Geneombio Technologies Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Geneombio Technologies Private Limited
Subsidiaries & Group Companies of Geneombio Technologies Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Geneombio Technologies Private Limited with ownership details.
MCA Filings & Documents of Geneombio Technologies Private Limited
MCA Filings & Documents of Geneombio Technologies Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Geneombio Technologies Private Limited
Recent News on Geneombio Technologies Private Limited
Frequently Asked Questions about Geneombio Technologies Private Limited
Geneombio Technologies Private Limited is an active private limited company in the healthcare sector based in Haveli, Maharashtra, India. It was incorporated on 06 July 2005 (21+ years old) and is registered under CIN U24239PN2005PTC020977. The company has 29 employees.
Geneombio Technologies Private Limited reported revenue of ₹6.07 Cr for FY 2024 (up 35.00% YoY).
The current directors of Geneombio Technologies Private Limited are:
The primary industry of Geneombio Technologies Private Limited is healthcare. The company specifically operates in diagnostic centers and pathology labs. The company is currently active in this sector.
Geneombio Technologies Private Limited can be reached at the registered office: Office No. 302 Third Floor Lalani Quantum, Survey No. 322A 3231A 3241A, Haveli, Maharashtra, India – 411021, or through the website geneombiotechnologies.com.
The authorised capital is ₹2.85 Cr, and the paid-up capital is ₹2.8 Cr.